SCHEMBL1363558

SCHEMBL1363558

O=Cc1cc(Cl)cs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12177559 0.76 ALAD (0.53)
SCHEMBL30104097 0.76 PGR (0.44)
SCHEMBL6922597 0.72 MAOA (0.40)
SCHEMBL1242209 0.72 HSD17B10 (0.38)
SCHEMBL23006 0.72
SCHEMBL346857 0.72
SCHEMBL14038839 0.71
SCHEMBL4389421 0.70 HCAR2 (0.47)
SCHEMBL4389413 0.70 HCAR2 (0.47)
SCHEMBL28060892 0.70 LMNA (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109369611-B Synthetic method of 4-chlorothiophene-2-carbonyl derivative 上海毕得医药科技有限公司 2020-11-10 CN claimed
CN-109369611-A A kind of synthetic method of 4- chlorothiophene -2- carbonyl derivative 上海毕得医药科技有限公司 2019-02-22 CN claimed
CN-104098558-A Amide compound and preparation method thereof CHANGZHOU NO 4 PHARMACEUTICAL FACTORY CO LTD 2014-10-15 CN claimed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
CN-117355521-A Heteroaryl inhibitors of plasma kallikrein 武田药品工业株式会社 2024-01-05 CN disclosed
US-11718607-B2 Atypical coupling method for the preparation of 1,2-di(thiophen-2-yl)ethene-1,2-diol compounds via a Cu(II) catalyst QATAR UNIVERSITY (QA) 2023-08-08 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2022197758-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed
US-20220204487-A1 ATYPICAL COUPLING METHOD FOR THE PREPARATION OF 1,2-DI(THIOPHEN-2-YL)ETHENE-1,2-DIOL COMPOUNDS VIA A CU(II) CATALYST QATAR UNIVERSITY (QA) 2022-06-30 US disclosed
EP-3676263-B1 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) 2021-10-06 EP disclosed
EP-1021410-A1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER INC. (US) 2000-07-26 EP disclosed
WO-2000032590-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-08 WO disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 WO disclosed
WO-1999019300-A1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER INC. (US) 1999-04-22 WO disclosed
EP-0874848-A1 PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1998-11-04 EP disclosed
WO-1997020843-A1 PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1997-06-12 WO disclosed
US-5145868-A 7-((Hydroxy(3-hydroxy-4-acylphenyl)alkylene)thio-),4-oxo-4H -chromene; antiallergens; leukotrienes antagonist CIBA-GEIGY CORPORATION (US) 1992-09-08 US disclosed
EP-0419410-A2 Alkanophenones CIBA-GEIGY AG (CH) 1991-03-27 EP disclosed
US-4192884-A Substituted 4-(((thienyl)methyl)-amino)benzoic acids and a method for treating hypolipidemia THE DOW CHEMICAL COMPANY (US) 1980-03-11 US disclosed